로딩 중…
지수 로딩 중…
MYUNGMOON PHARM CO.,LTD
017180· KOSPI· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩1,114-1.76%
2026-11-03
Financials
Valuation Metrics
MYUNGMOON PHARM CO.,LTD's Market Cap is ₩378B. At end of 2025 it was ₩628B. Ranked #1873 of 2,405 in KR market (top 78%), #713 of 778 on KOSPI (top 92%), #199 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 86%) by Market Cap.
Investment Metrics(as of 2026-11-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 37.82B KRW | KR#1,873/2,405 Sec#199/231 |
| Revenue | 199.82B KRW | KR#1,040/2,405 Sec#62/231 |
| Net Income | -2.57B KRW | KR—/2,405 Sec—/231 |
| Total Assets | 300.16B KRW | KR#1,035/2,405 Sec#70/231 |
| Net Assets | 102.64B KRW | KR#1,393/2,405 Sec#110/231 |
| Employees | 297 | KR#793/2,405 Sec#68/231 |
| Value | ||
| P/B | 0.37x | KR#591/2,405 Sec#21/231 |
| P/S | 0.19x | KR#394/2,405 Sec#8/231 |
| EV/EBITDA | 112.23x | KR#1,504/2,405 Sec#100/231 |
| Profitability | ||
| ROE | -2.50% | KR#1,706/2,405 Sec#121/231 |
| ROA | -0.85% | KR#1,658/2,405 Sec#114/231 |
| Op. Margin | 0.76% | KR#1,524/2,405 Sec#106/231 |
| Revenue Growth | 4.75% | KR#1,206/2,405 Sec#118/231 |
| Earnings Growth | -156.83% | KR#1,209/2,405 Sec#78/231 |
| Financial Health | ||
| Debt Ratio | 192.44% | KR#2,070/2,405 Sec#216/231 |
| Total Debt | 157.21B KRW | KR#591/2,405 Sec#32/231 |
| Cash | 24.08B KRW | KR#1,135/2,405 Sec#76/231 |
| Current Ratio | 1.06x | KR#1,642/2,405 Sec#164/231 |
| Net Debt/EBITDA | 87.40x | KR#1,511/2,405 Sec#105/231 |
| Dividend | ||
| Div. Growth | 18.83% | KR#470/2,405 Sec#25/231 |
| Performance | ||
| 1Y Return | -29.63% | KR#1,411/2,405 Sec#109/231 |
| 1M Return | -12.49% | KR#1,239/2,405 Sec#117/231 |
| From 52W High | -45.79% | KR#946/2,405 Sec#64/231 |
| 1Y MDD | -45.66% | KR#767/2,405 Sec#57/231 |
| Trading | ||
| Volume | 54,936 shares | KR#1,071/2,405 Sec#113/231 |
| Trading Value | 61.2M KRW | KR#1,740/2,405 Sec#184/231 |
| Foreign Own. | 2.20% | KR#1,549/2,405 Sec#147/231 |
| Per Share | ||
| EPS | -76 KRW | KR—/2,405 Sec—/231 |
| BPS | 3,023 KRW | KR#1,867/2,405 Sec#141/231 |
Company Info
동사는 1983년 설립된 제약회사로, 2018년 제2공장을 신축하고, 2024년 종속회사 명문바이오가 GMP 인증을 획득하여 의약품 공급 및 매출 성장 기반을 마련함. 의약품부문에서 경피흡수제형 패취제와 고혈압, 당뇨, 항암제 등을 연구 및 출시하고 있으며, 서비스부문에서는 골프클럽을 운영하고 있음. 인구고령화에 따른 의약품 수요 증가와 난치성 질환 치료제 시장 성장에 대응하여 매출액의 약 2.49%를 연구 개발에 투자하고 있음. 명문제약는 1983년에 설립되었으며 경기도 화성시에 본사를 두고 있습니다.